Avidity biosciences announces fda partial clinical hold on new participant enrollment in phase 1/2 marina™ trial

Participants currently enrolled in marina and marina-ole™ trials may continue to be treated with aoc 1001 avidity received investigational new drug (ind) clearance for fshd and dmd studies from fda; programs now advancing into the clinic company to host investor webcast today at 8:30 a.m. et / 5:30 a.m.
RNA Ratings Summary
RNA Quant Ranking